MEG are non invasive neuroimaging techniques with excellent temporal and spatial resolution, crucial for studying brain function in dementia and Alzheimer Disease. They identify changes in brain activity at various Alzheimer stages, including preclinical and prodromal phases. MEG may detect pathological changes before clinical symptoms, offering potential biomarkers for intervention. This study evaluates classification techniques using MEG features to distinguish between healthy controls and mild cognitive impairment participants from the BioFIND study. We compare MEG based biomarkers with MRI based anatomical features, both independently and combined. We used 3 Tesla MRI and MEG data from 324 BioFIND participants;158 MCI and 166 HC. Analyses were performed using MATLAB with SPM12 and OSL toolboxes. Machine learning analyses, including 100 Monte Carlo replications of 10 fold cross validation, were conducted on sensor and source spaces. Combining MRI with MEG features achieved the best performance; 0.76 accuracy and AUC of 0.82 for GLMNET using LCMV source based MEG. MEG only analyses using LCMV and eLORETA also performed well, suggesting that combining uncorrected MEG with z-score-corrected MRI features is optimal.